<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713153</url>
  </required_header>
  <id_info>
    <org_study_id>2.4.9</org_study_id>
    <nct_id>NCT01713153</nct_id>
  </id_info>
  <brief_title>Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal</brief_title>
  <official_title>Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChildFund International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a large, community-based, cluster-randomized trial to compare routine prophylactic
      use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly
      during the third stage of labor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the programmatic implications (including feasibility, acceptability,
      risks and benefits) at the community level of the introduction of misoprostol and/or oxytocin
      in UnijectTM for the prevention of PPH and will help to identify the appropriate niche for
      both drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in hemoglobin</measure>
    <time_frame>during 3rd trimester and 1-3 days postpartum</time_frame>
    <description>To establish the comparable effectiveness of two technologies, individual pre- and post-delivery Hb measures will be taken to calculate change in Hb. This will be done using a Hemocue Hemoglobin machine + cuvette (HemoCue, Angelholm, Sweden). The Hemocue is a simple means of collecting Hb measures at the community-level where traditional laboratory techniques are not feasible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and management of side effects</measure>
    <time_frame>1 hour postpartum</time_frame>
    <description>nausea, vomiting, diarrhea, shivering, fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correct timing of drug administration</measure>
    <time_frame>collected immediately following birth, verified 1-3 days postpartum</time_frame>
    <description>administration of the drug after the birth of the baby and verifying no twin, before the expulsion of the placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hemoglobin â‰¥ 2 g/dL</measure>
    <time_frame>during third trimester and 1-3 days postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional interventions</measure>
    <time_frame>during birth</time_frame>
    <description>use of additional uterotonics, manual removal of placental fragments, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>referrals</measure>
    <time_frame>0-3 days postpartum</time_frame>
    <description>referral requested, transfers carried out, reasons for incomplete referrals/transfers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptability</measure>
    <time_frame>1-3 days postpartum</time_frame>
    <description>acceptability according to woman of study medication, care received, side effects experienced</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1365</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mcg oral misoprostol administered during the third stage of labor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UnijectTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 IU oxytocin delivered IM with UnijectTM during he third stage of labor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>600 mcg misoprostol oral</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
    <other_name>Misoclear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UnijectTM</intervention_name>
    <description>10 IU oxytocin delivered intramuscularly with UnijectTM</description>
    <arm_group_label>UnijectTM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women delivering in community health centers (case de sante) with a trained study
             provider (matrone) who are able to provide informed consent

        Exclusion Criteria:

          -  women with known contraindications to prostaglandins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Health huts in the district of Thiadiaye and Kolda</name>
      <address>
        <city>Thiadiay and Kolda</city>
        <state>Thiadiaye and Kolda</state>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>http://gynuity.org/programs/more/prevention-of-postpartum-prevention</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>prevention</keyword>
  <keyword>misoprostol</keyword>
  <keyword>Uniject</keyword>
  <keyword>oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

